TABLE 6.
In vitro activity of glecaprevir against amino acid substitutions observed in DAA-experienced HCV GT1b-infected patients
| NS3 amino acid substitution(s)a | Mean glecaprevir EC50 ± SD (nM) | Fold change in EC50 |
|---|---|---|
| GT1b wild type | 0.47 ± 0.13 | |
| Q80K | 0.37 ± 0.03 | 0.8 |
| Q80L | 0.30 ± 0.07 | 0.6 |
| A156V | 839 ± 181 | 1,786 |
| D168A | 0.69 ± 0.11 | 1.5 |
| D168E | 0.40 ± 0.08 | 0.9 |
| D168T | 1.3 ± 0.20 | 2.8 |
| D168V | 1.5 ± 0.43 | 3.2 |
| A156V + D168V | 2,465 ± 1,321 | 5,244 |
a
Amino acid substitutions that were detected at baseline or at the time of failure in patients experiencing virologic failure are underlined.